The Italian Observational Study on Severe Osteoporosis (ISSO): 24-month results on incidence of fractures and adherence to treatment

被引:0
|
作者
Idolazzi, L. [1 ]
Maugeri, D. [2 ]
Monti, S. [3 ]
Massarotti, M. [4 ]
Osella, G. [5 ]
Barbagallo, M. [6 ]
Del Fiacco, R. [7 ]
Silvestri, S. [7 ]
机构
[1] Univ Verona, Dept Med, Lilly Rheumatol Unit, I-37100 Verona, Italy
[2] Univ Catania, Cannizzaro Hosp, Geriatr Unit, Catania, Italy
[3] Univ Roma La Sapienza, St Andrea Hosp, Dept Endocrinol, Rome, Italy
[4] Humanitas Res Hosp, Div Rheumatol & Clin Immunol, Rozzano, Italy
[5] Univ San Luigi Gonzaga, Azienda Osped, Med Interna, Orbassano, Italy
[6] Univ Palermo, Dept Internal Med & Geriatr DIBIMIS, Geriatr Unit, I-90133 Palermo, Italy
[7] Lilly Italia, Dept Med, Sesto Fiorentino, Italy
关键词
spine; spinal fractures; observational study; teriparatide; parathyroid hormone; osteoporosis; fractures; osteoporosis therapy; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; NONVERTEBRAL FRACTURES; VERTEBRAL FRACTURE; RISK; TRIAL; THERAPY;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To estimate the proportion of patients with very severe osteoporosis (those covered by the reimbursement criteria of the Italian National Health Service) experiencing new vertebral and non-vertebral fragility fractures in the first 24 months of a new anti-osteoporosis treatment. Methods Prospective observational study in men and post-menopausal women (aged > 21 years) initiating anti-osteoporosis treatment for very severe osteoporosis. Eligibility was based on teriparatide (TPD) reimbursement criteria in Italy: incident of vertebral or hip fracture during anti-resorptive treatment (minimum 1 year), or at least three prevalent severe vertebral fractures, or two prevalent severe vertebral fractures and a historical proximal hip fracture. Incidence of new clinical vertebral and non-vertebral fractures was documented by original x-rays and/or radiological reports, and a post-hoc analysis compared data from the TPD monotherapy population versus the total treated group. Results Overall, 767 patients (mean age 72.8 years, 90.7% women) were enrolled in the study, of whom 628, 538, 419 and 424 attended visits at 6, 12, 18 and 24 months, respectively. The most commonly prescribed therapy was TPD (single-agent; 64.5%), then bisphosphonates and other anti-resorptives (33.3%). A combination of different oral treatments was given to 22.5% of the patients. Overall treatment adherence at 24 months was 65.7%. In a post-hoc analysis, the overall incidence of new clinical vertebral and non-vertebral fractures in the total treated population was, respectively, 4.7% and 2.3% in the first 6 months; 1.8% and 1.6% in the 6-12 month period; 2.9% and 1.4% in the 12-18 month period; and 2.2% and 1.0% in the 18-24 month period. Conclusion In patients with very severe osteoporosis, the risk of new vertebral and non-vertebral fractures declined after the first 6 months and remained low throughout the study.
引用
收藏
页码:247 / 253
页数:7
相关论文
共 50 条
  • [1] Baseline charateristics of the population enrolled in the Italian Observational Study on Severe Osteoporosis (ISSO)
    Adami, S.
    Maugeri, D.
    Toscano, V.
    Topa, G.
    Caminiti, M.
    Brancati, A.
    Massarotti, M.
    Osella, G.
    Malavolta, N.
    Iolascon, G.
    Cagnoni, C.
    Camozzi, V.
    Corradini, C.
    Nardi, A.
    Migliaccio, S.
    Ulivieri, F. M.
    Resmini, G.
    Valle, D.
    Tauchmanova, L.
    Silvestri, S.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (03) : 477 - 484
  • [2] Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS)
    Langdahl, Bente L.
    Ljunggren, Osten
    Benhamou, Claude-Laurent
    Marin, Fernando
    Kapetanos, George
    Kocjan, Tomaz
    Lespessailles, Eric
    Napoli, Nicola
    Nikolic, Tatjana
    Petto, Helmut
    Moll, Thomas
    Lindh, Erik
    CALCIFIED TISSUE INTERNATIONAL, 2016, 99 (03) : 259 - 271
  • [3] Osteoporosis and prostate cancer; a 24-month prospective observational study during androgen deprivation therapy
    Poulsen, Mads Hvid
    Frost, Morten
    Abrahamsen, Bo
    Gerke, Oke
    Walter, Steen
    Lund, Lars
    SCANDINAVIAN JOURNAL OF UROLOGY, 2019, 53 (01) : 34 - 39
  • [4] Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan Fracture Observational Study (JFOS)
    Soen, Satoshi
    Fujiwara, Saeko
    Takayanagi, Ryoichi
    Kajimoto, Kenta
    Tsujimoto, Mika
    Kimura, Shuichi
    Sato, Masayo
    Krege, John H.
    Enomoto, Hiroyuki
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (11) : 2049 - 2056
  • [5] Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS)
    Bente L. Langdahl
    Östen Ljunggren
    Claude-Laurent Benhamou
    Fernando Marin
    George Kapetanos
    Tomaz Kocjan
    Eric Lespessailles
    Nicola Napoli
    Tatjana Nikolic
    Helmut Petto
    Thomas Moll
    Erik Lindh
    Calcified Tissue International, 2016, 99 : 259 - 271
  • [6] Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS)
    Napoli, Nicola
    Langdahl, Bente. L.
    Ljunggren, Osten
    Lespessailles, Eric
    Kapetanos, George
    Kocjan, Tomaz
    Nikolic, Tatjana
    Eiken, Pia
    Petto, Helmut
    Moll, Thomas
    Lindh, Erik
    Marin, Fernando
    CALCIFIED TISSUE INTERNATIONAL, 2018, 103 (04) : 359 - 371
  • [7] Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis
    Black, D. M.
    Bilezikian, J. P.
    Greenspan, S. L.
    Wuester, C.
    Munoz-Torres, M.
    Bone, H. G.
    Rosen, C. J.
    Andersen, H. S.
    Hanley, D. A.
    OSTEOPOROSIS INTERNATIONAL, 2013, 24 (04) : 1503 - 1511
  • [8] Sequential Treatment of Severe Postmenopausal Osteoporosis After Teriparatide: Final Results of the Randomized, Controlled European Study of Forsteo (EUROFORS)
    Eastell, Richard
    Nickelsen, Thomas
    Marin, Fernando
    Barker, Clare
    Hadji, Peyman
    Farrerons, Jordi
    Audran, Maurice
    Boonen, Steven
    Brixen, Kim
    Gomes, Jose Melo
    Obermayer-Pietsch, Barbara
    Avramidis, Avraam
    Sigurdsson, Gunnar
    Glueer, Claus C.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2009, 24 (04) : 726 - 736
  • [9] The adult growth hormone multicentric retrospective observational study: a 24-month Italian experience of adherence monitoring via Easypod™ of recombinant growth hormone treatment in adult GH deficiency
    Mancini, Antonio
    Vergani, Edoardo
    Bruno, Carmine
    Giavoli, Claudia
    Spaziani, Matteo
    Isidori, Andrea M.
    Arosio, Maura
    Pontecorvi, Alfredo
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [10] Effectiveness of Teriparatide in Women Over 75 Years of Age with Severe Osteoporosis: 36-Month Results from the European Forsteo Observational Study (EFOS)
    Walsh, J. Bernard
    Lems, Willem F.
    Karras, Dimitrios
    Langdahl, Bente L.
    Ljunggren, Osten
    Fahrleitner-Pammer, Astrid
    Barrett, Annabel
    Rajzbaum, Gerald
    Jakob, Franz
    Marin, Fernando
    CALCIFIED TISSUE INTERNATIONAL, 2012, 90 (05) : 373 - 383